RS61611B1 - Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja - Google Patents
Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećajaInfo
- Publication number
- RS61611B1 RS61611B1 RS20210230A RSP20210230A RS61611B1 RS 61611 B1 RS61611 B1 RS 61611B1 RS 20210230 A RS20210230 A RS 20210230A RS P20210230 A RSP20210230 A RS P20210230A RS 61611 B1 RS61611 B1 RS 61611B1
- Authority
- RS
- Serbia
- Prior art keywords
- mice
- gtb
- eae
- pharmaceutical composition
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928622P | 2014-01-17 | 2014-01-17 | |
| PCT/US2015/011798 WO2015109215A1 (en) | 2014-01-17 | 2015-01-16 | The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs |
| EP15737329.1A EP3094616B1 (en) | 2014-01-17 | 2015-01-16 | The use of glyceryl tribenzoate containing composition in neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61611B1 true RS61611B1 (sr) | 2021-04-29 |
Family
ID=53543490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210230A RS61611B1 (sr) | 2014-01-17 | 2015-01-16 | Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9968582B2 (enExample) |
| EP (1) | EP3094616B1 (enExample) |
| JP (2) | JP6836905B2 (enExample) |
| CA (1) | CA2936548C (enExample) |
| CY (1) | CY1124115T1 (enExample) |
| DK (1) | DK3094616T3 (enExample) |
| ES (1) | ES2853974T3 (enExample) |
| HR (1) | HRP20210361T1 (enExample) |
| HU (1) | HUE053671T2 (enExample) |
| LT (1) | LT3094616T (enExample) |
| PL (1) | PL3094616T3 (enExample) |
| PT (1) | PT3094616T (enExample) |
| RS (1) | RS61611B1 (enExample) |
| SI (1) | SI3094616T1 (enExample) |
| SM (1) | SMT202100074T1 (enExample) |
| WO (1) | WO2015109215A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691630A4 (en) * | 2017-10-06 | 2021-10-27 | Rush University Medical Center | USE OF A COMPOSITION CONTAINING BENZOATE TO TREAT GLYCINE ENCEPHALOPATHY |
| AU2018371628B2 (en) | 2017-11-22 | 2021-08-12 | Excelsior Pharmatech Labs | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
| EA202192199A1 (ru) * | 2019-02-25 | 2021-12-17 | Раш Юниверсити Медикал Сентер | Композиции, содержащие коричную кислоту, и способы их применения |
| KR20220066253A (ko) * | 2019-07-16 | 2022-05-24 | 러쉬 유니버시티 메디컬 센터 | 신경퇴행성 장애를 치료하기 위한 벤조에이트 함유 조성물의 용도 |
| WO2022093922A1 (en) | 2020-10-28 | 2022-05-05 | Rush University Medical Center | Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders |
| EP4262781A4 (en) * | 2020-12-16 | 2025-02-12 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| US20250057793A1 (en) * | 2021-12-16 | 2025-02-20 | The United States Government As Represented By The Department Of Veterans Affairs | Benzoic acid salts for treatment of nervous system injuries and disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US20080171792A1 (en) * | 2006-12-28 | 2008-07-17 | Jobdevairakkam Christopher New | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders |
-
2015
- 2015-01-16 HU HUE15737329A patent/HUE053671T2/hu unknown
- 2015-01-16 PT PT157373291T patent/PT3094616T/pt unknown
- 2015-01-16 LT LTEP15737329.1T patent/LT3094616T/lt unknown
- 2015-01-16 PL PL15737329T patent/PL3094616T3/pl unknown
- 2015-01-16 ES ES15737329T patent/ES2853974T3/es active Active
- 2015-01-16 SI SI201531511T patent/SI3094616T1/sl unknown
- 2015-01-16 US US15/110,702 patent/US9968582B2/en active Active
- 2015-01-16 HR HRP20210361TT patent/HRP20210361T1/hr unknown
- 2015-01-16 JP JP2016565117A patent/JP6836905B2/ja active Active
- 2015-01-16 CA CA2936548A patent/CA2936548C/en active Active
- 2015-01-16 SM SM20210074T patent/SMT202100074T1/it unknown
- 2015-01-16 WO PCT/US2015/011798 patent/WO2015109215A1/en not_active Ceased
- 2015-01-16 EP EP15737329.1A patent/EP3094616B1/en active Active
- 2015-01-16 RS RS20210230A patent/RS61611B1/sr unknown
- 2015-01-16 DK DK15737329.1T patent/DK3094616T3/da active
-
2019
- 2019-10-18 JP JP2019191224A patent/JP2020037558A/ja active Pending
-
2021
- 2021-03-09 CY CY20211100204T patent/CY1124115T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3094616T3 (da) | 2021-02-15 |
| ES2853974T3 (es) | 2021-09-20 |
| CA2936548A1 (en) | 2015-07-23 |
| SI3094616T1 (sl) | 2021-07-30 |
| CY1124115T1 (el) | 2022-05-27 |
| CA2936548C (en) | 2022-08-30 |
| JP6836905B2 (ja) | 2021-03-03 |
| LT3094616T (lt) | 2021-04-12 |
| PL3094616T3 (pl) | 2021-05-31 |
| JP2017505811A (ja) | 2017-02-23 |
| SMT202100074T1 (it) | 2021-05-07 |
| US9968582B2 (en) | 2018-05-15 |
| EP3094616B1 (en) | 2020-12-23 |
| WO2015109215A1 (en) | 2015-07-23 |
| HUE053671T2 (hu) | 2021-07-28 |
| JP2020037558A (ja) | 2020-03-12 |
| US20160331714A1 (en) | 2016-11-17 |
| EP3094616A1 (en) | 2016-11-23 |
| EP3094616A4 (en) | 2017-08-23 |
| HRP20210361T1 (hr) | 2021-04-16 |
| PT3094616T (pt) | 2021-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3094616B1 (en) | The use of glyceryl tribenzoate containing composition in neurodegenerative disorders | |
| JP5712207B2 (ja) | 脳疾患及び状態の予防及び治療のための組成物及び方法 | |
| EP3528835B1 (fr) | Compositions antivirales pour le traitement des infections liees aux coronavirus | |
| AU2014260468A1 (en) | Sobetirome in the treatment of myelination diseases | |
| JP6529634B1 (ja) | アミロイドβ分解排出促進剤 | |
| US20120237482A1 (en) | Methods for treatment of neurological disorders by modulation of microglial activation | |
| US11207331B2 (en) | Agents, compositions and methods for enhancing neurological function | |
| JP2020502278A (ja) | 青黛抽出物又はその分画物を有効成分として含む炎症性腸疾患の予防又は治療のための医薬組成物 | |
| AU2022200277A1 (en) | The use of a benzoate containing composition to treat glycine encephalopathy | |
| JP2022521233A (ja) | 桂皮酸を含む組成物及びその使用方法 | |
| CN108210818B (zh) | 一种防治神经退行性疾病的药物组合物及其制备方法和用途 | |
| Bachert et al. | Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis | |
| CN106361738A (zh) | 治疗、预防脑白质损伤的医药组合物及其医药用途 | |
| CN115429799A (zh) | Magl抑制剂在制备预防或治疗肝炎药物中的用途 | |
| CN116390761A (zh) | 肉桂酸苄酯组合物在治疗甘氨酸脑病和尿素循环障碍中的应用 | |
| WO2005002568A1 (fr) | Utilisation de 1-n-butylphtalide pour la prevention ou les traitements de la demence | |
| CN104411308A (zh) | 通过给予某些合成化合物治疗阿尔茨海默病的方法 | |
| CN114984017A (zh) | 用于中枢神经系统脱髓鞘疾病治疗的化合物 | |
| CN120983423B (zh) | 狭叶依瓦菊素在制备预防和/或治疗神经炎症的药物中的用途 | |
| US20230201134A1 (en) | Compositions for the management of demyelinating disorders | |
| CN114984034A (zh) | 一种寡糖类化合物的应用 | |
| CN113057977A (zh) | 一种改善学习记忆的片剂及其制备方法 | |
| HK40015331B (en) | Brain function-improving agent, food, and medicine using lipopolysaccharide | |
| CN107281206A (zh) | 黑升麻苷在制备防治老年性痴呆药物中的应用 | |
| JP2016102068A (ja) | 鯨筋肉抽出物からなる中長期記憶障害予防改善剤 |